FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.
Location: United States, California, San Francisco
Employees: 201-500
Founded date: 1993
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Scientia V... | scientiavc... |
| - | Omega Fund... | omegafunds... |
| - | Ridgeback ... | ridgebackc... |
| - | Hony Capit... | honycapita... |
Mentions in press and media 11
| Date | Title | Description |
| 08.08.2024 | Appointment of Chief Financial Officer | Appointment of Chief Financial Officer Thu, Aug 08, 2024 08:00 CET Report this content Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Appointment of Chief Financial Officer Company announcement, 8 August 2024 at 2:00 a.m. EDT / 7:00 ... |
| 07.11.2022 | FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management | - |
| 27.11.2020 | Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis | |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 12.08.2011 | Beyond EPO injections: Anemia treatment that comes in a pill | The anemia market could be worth up to $10 billion annually. It’s dominated by injectable biologic drugs, such as Amgen’s Epogen and Aranesp and Johnson & Johnson’s Procrit, with Amgen holding most of the market. Those drugs generally w... |
| 21.06.2010 | Akebia Therapeutics aims at needs of chronic anemia patients | Pharmaceutical companies have developed injectable drugs, called erythropoietin-stimulating agents (ESAs), to treat chronic anemia. But the drugs that boost erythropoietin — the hormone that stimulates the bone marrow to make more red blood... |
| 16.06.2010 | Akebia Therapeutics gets thumbs up from clinical trial, investors | Startup Akebia is racing to the finish line with big drug companies toward a $10 billion-a-year worldwide market for a safe, effective, affordable oral treatment for chronic anemia. So far, there are no oral small-molecule drugs to treat ch... |
| 10.05.2007 | Roundup: Anemia drugs under assault, stem-cell trial moves forward, medical interventions and poor “quality of death,” and more | Is the bell tolling for EPO? — The news keeps going from bad to worse for the wonder drugs of biotech — the anemia treatments known as ESAs or EPO, shorthand for “erythropoiesis stimulating agents” and “erythropoietin,” respectively. Earlie... |
| - | Akebia Therapeutics aims at needs of chronic anemia patients | Being first isn’t the only goal in the drug-development business. Sometimes, an unmet patient need is so great, companies that are second or third to market stand a good chance of success. That’s what Akebia Therapeutics Inc. near Cincinnat... |
| - | Beyond EPO injections: Anemia treatment that comes in a pill | The pharmaceutical company Affymax just got $10 million for moving forward with an anemia treatment that would require one injection a month as opposed to as many as several shots a week. Imagine the opportunity if someone can take a simila... |
Show more